Thrombolysis in patients with diabetes

doi:10.1136/bmj.310.6985.1008a

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

More evidence that the treatment should not necessarily be withheld

D K Newman,
M P Snead,
D W Flanagan,
J D Scott

Registrar in ophthalmology Senior registrar in ophthalmology Consultant ophthalmologist Consultant ophthalmologist Department of Ophthalmology, Addenbrooke's Hospital, Cambridge CB2 2QQ

EDITOR,—Helen Ward and John S Yudkin rightly draw attention to the lack of evidence that thrombolytic treatment for acute myocardial infarction may precipitate vitreous haemorrhage in patients with diabetic retinopathy.1 Two additional points strengthen their argument that the treatment should not necessarily be withheld in such patients.

Firstly, consideration of the pathophysiology of diabetic vitreous haemorrhage …